News Update

PM, V-P to hold straight talk with All States’ Governors on worsening COVID-19 situationJustice Chandrachud inaugurates portals for judgements, e-filing 3.0Indian industrial output contracts 3.6% in FebUnidentified gunman shoots dead oner person & seriously injures another in Paris hospitalMarch retail inflation rises to 5.52%GST - 'Air Springs' act as shock absorber designed specifically for Motor Vehicles - rightly classifiable under CTH 8708 attracting @28% and not under CTH 4016 @18%: AARGST - 'Polypropylene Non-woven Bags' is classifiable under HSN 3923 at 18% and not at 5% under 6305: AARIndian regulator grants nod to Russian Sputnik V vaccineGST - 'Wheat' imported is destined to importer's factory for further processing and it is not to the primary market - Therefore, services of loading, unloading, packing, storage or warehousing is not entitled to exemption under 12/2017-CTR: AARMassive blaze at Russia’s historic St Petersburg factory; dozens evacuatedST - SVLDRS - Disagreement over estimated amount - No specific record made available by Revenue that communication of hearing was sent on 'email id' or via 'SMS' - SVLDRS-3 set aside: HCCus - Issue is purely contractual between petitioner, on the one hand and private respondents on the other - In such a case, it would not be open to the Writ Court to issue any Mandamus: HCPresident Kovind discharged from AIIMS after bypass surgeryGST - All stakeholders are treading in the new GST regime with uncertainties as the path is comparatively unfamiliar, unmarked and unpaved - Order of detention is an example of such uncertainty: HCSoaring COVID-19 cases - Drug Inspectors to monitor stocks of RemdesivirVAT - Bill of Entry cannot be regarded as title to goods as per provisions of Customs Act: HCI-T - Provisions of sec. 2(22)(e) are not applicable when assessee is not a shareholder: ITATRising COVID-19 cases - India embargoes export of Remdesivir and its API
 
Bharat Biotech announces Covaxin Phase 3 results, says interim vaccine efficacy of 81 per cent

By TIOL News Service

NEW DELHI, MAR 04, 2021: BHARAT Biotech on Wednesday announced their homegrown COVID-19 vaccine, Covaxin has shown an interim vaccine efficacy of 81 per cent in late-stage clinical trials.

The Phase 3 results of Covaxin, jointly initiated by the Indian Council of Medical Research (ICMR) and Bharat Biotech in mid-November, involved 25,800 volunteers between 18-98 years of age across 21 sites.

"The interim efficacy trend of 81 per cent, analysed as per the protocol approved by the Drugs Controller General of India (DCGI), puts it at par with other global front-runner vaccines," said Bharat Biotech.

They have now reported data from all three phases of trials.

"The bench-to-bedside journey of completely indigenous COVID-19 vaccine in less than 8 months' time showcases the immense strength of Aatmanirbhar Bharat [self-reliant India] to fight the odds and stand tall in the global public health community. It is also a testament to India's emergence as a global vaccine superpower," said Mr Balram Bhargava, Director General, ICMR.

Covaxin is the first indigenously developed and manufactured COVID-19 vaccine candidate and has been granted emergency use approval by the DCGI in January for "restricted use in an emergency situation."


POST YOUR COMMENTS